Drug Profile


Alternative Names: Anti-IL-13 monoclonal antibody - MedImmune; Anti-interleukin-13 monoclonal antibody - MedImmune; CAT-354

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 03 Mar 2017 Efficacy and adverse events data from a phase IIb trial in Atopic Dermatitis released by LEO Pharma
  • 01 Nov 2016 AstraZeneca initiates enrolment in a phase III trial for Asthma (In adolescents, In adults, Treatment-experienced) in Japan (SC) (NCT02902809)
  • 13 Sep 2016 AstraZeneca plans a phase III trial for Asthma (In adolescents, In adults, Treatment-experienced) in Japan (SC) (NCT02902809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top